Literature DB >> 31082277

Screening, diagnosis and risks associated with Hepatitis E virus infection.

Sébastien Lhomme1,2,3, Florence Legrand-Abravanel1,2,3, Nassim Kamar2,3,4, Jacques Izopet1,2,3.   

Abstract

Introduction: Hepatitis E virus (HEV) is the main cause of hepatitis worldwide. Our knowledge of this single-strand positive-sense RNA virus, discovered in the 1980s, has improved greatly in recent years. Areas covered: We review the most recent information on diagnostic tools, including serological and molecular assays, the recommended diagnostic algorithm, and the clinical manifestations of HEV infections. Expert opinion: The performance of serological and molecular assays has improved greatly in recent years and the availability of a WHO standard has been invaluable for comparing the performance of molecular assays. The more efficient serological and molecular assays have led to a clearer picture of HEV epidemiology. It is now established that HEV is distributed worldwide. The European Association for the Study of the Liver (EASL) now recommends testing for anti-HEV IgM and HEV RNA. Molecular tests indicate that HEV RNA is very common in asymptomatic blood donors. The description of transfusion-transmitted HEV makes having optimal strategies essential for improving blood safety. Like other hepatitis viruses, HEV infection must be suspected whenever a patient presents with clinical or biochemical features of hepatitis. An HEV infection can also have extra-hepatic manifestations, especially neurological and renal disorders.

Entities:  

Keywords:  Hepatitis E virus; diagnosis algorithm; molecular diagnosis; neurological manifestations; renal manifestations; serological test

Mesh:

Substances:

Year:  2019        PMID: 31082277     DOI: 10.1080/14787210.2019.1613889

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  6 in total

1.  Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay.

Authors:  Florence Abravanel; Delphine Parraud; Sabine Chapuy-Regaud; Marcel Miedouge; Estelle Bonnin; Margaux Larrieu; Alexandre Aversenq; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2022-05-17       Impact factor: 5.818

Review 2.  Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections.

Authors:  Sébastien Lhomme; Olivier Marion; Florence Abravanel; Jacques Izopet; Nassim Kamar
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

3.  Prognostic Significance of End-Stage Liver Diseases, Respiratory Tract Infection, and Chronic Kidney Diseases in Symptomatic Acute Hepatitis E.

Authors:  Huahao Fan; Junfen Fan; Suming Chen; Yangzhen Chen; Huiru Gao; Liying Shan; Xue Li; Fengjun Gu; Hui Zhuang; Lijun Sun
Journal:  Front Cell Infect Microbiol       Date:  2021-01-15       Impact factor: 5.293

Review 4.  Towards the Improved Accuracy of Hepatitis E Diagnosis in Vulnerable and Target Groups: A Global Perspective on the Current State of Knowledge and the Implications for Practice.

Authors:  Jasminka Talapko; Tomislav Meštrović; Emina Pustijanac; Ivana Škrlec
Journal:  Healthcare (Basel)       Date:  2021-01-29

Review 5.  Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology.

Authors:  Sébastien Lhomme; Florence Abravanel; Pascal Cintas; Jacques Izopet
Journal:  Pathogens       Date:  2021-12-03

6.  Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection.

Authors:  Antonio Rivero-Juarez; Pedro Lopez-Lopez; Juan Antonio Pineda; Juan Carlos Alados; Ana Fuentes-López; Encarnación Ramirez-Arellano; Carolina Freyre; Ana Belén Perez; Mario Frias; Antonio Rivero
Journal:  Microbiol Spectr       Date:  2021-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.